Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

FLNA stock hub

Filana Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FLNAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

62.8M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

FLNA

In the news

Latest news · FLNA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-79.6

P25 -105.6P50 -46.5P75 -3.1

ROIC-29.8

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FLNA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

171

Groups with data

Currency

USD

Showing 171 of 171 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001069530
Company name	Filana Therapeutics, Inc.
Country	United States
Country code	US
Cusip	14817C107
Employees	20
Employees Change	-10%
Employees Change Percent	-33.33
Enterprise value	$-23.8M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US14817C1071
Last refreshed	2026-05-10
Market cap	$62.8M
Market cap category	Micro-Cap
Price	$1.3
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	FLNA
Website	https://www.filanatx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-124.05%
P/B ratio	0.92x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-26.6M
Net Income	$-77.9M
Net Income Growth Quarters	3%
Net Income Growth Years	0%
Profit Per Employee	$-3.9M
ROA	-23.4
Roa5y	-30.81
ROCE	-68.38
ROE	-79.59
Roe5y	-40.7
ROIC	-29.8

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-22.58%
Cagr15y	-21.15%
Cagr1y	-16.68%
Cagr20y	-15.26%
Cagr3y	-61.23%
Cagr5y	-49.96%
EPS Growth Quarters	3
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$108.4M
Cash	$86.6M
Current Assets	$88M
Current Liabilities	$40.1M
Equity	$68.1M
Liabilities	$40.2M
Long Term Assets	$20.4M
Long Term Liabilities	$111,000
Net Cash	$86.6M
Net Cash By Market Cap	$138
Net Cash Growth	-26.21%
Net Debt Equity	$-1.27
Tangible Book Value	$68.1M
Tangible Book Value Per Share	$1.41
WACC	0.07

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.19
Net Working Capital	$-38.7M
Quick ratio	2.16
Working Capital	$47.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.39%
Dividend per share	$0
Dividend Yield	0%
Last Dividend	$5.25

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-92.26%
1Y total return	-16.67%
200-day SMA	2.43
3Y total return	-94.18%
50-day SMA	1.77
50-day SMA vs 200-day SMA	50under200
5Y total return	-96.86%
All Time High	184.6
All Time High Change	-99.3%
All Time High Date	2000-07-14
All Time Low	0.76
All Time Low Change	71.05%
All Time Low Date	2018-12-24
ATR	0.1
Beta	-0.76
Beta1y	1.31
Beta2y	0.77
Ch YTD	-34.34
High	1.35
High52	4.98
High52 Date	2025-10-16
High52ch	-73.9%
Low	1.27
Low52	1.27
Low52 Date	2026-05-08
Low52ch	2.28%
Ma50ch	-26.47%
Price vs 200-day SMA	-46.5%
RSI	30.19
RSI Monthly	35.55
RSI Weekly	31.23
Sharpe ratio	0.19x
Sortino ratio	0.39
Total Return	-1.39%
Tr YTD	-34.34
Tr15y	-97.17%
Tr1m	-22.16%
Tr1w	-13.91%
Tr3m	-35.96%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Earnings EPS Estimate	$-0.23
Operating Income	$-46.7M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	45,049,885%
Float Percent	93.26%
Shares Insiders	6.74%
Shares Institutions	28.36%
Shares Out	48,307,896
Shares Qo Q	0%
Shares Yo Y	1.39%
Short Float	15.37%
Short Ratio	19.04
Short Shares	14.34

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	457,080.35x
Bv Per Share	1.41
Ch10y	-92.26
Ch15y	-97.84
Ch1m	-22.16
Ch1w	-13.91
Ch1y	-16.67
Ch20y	-97.88
Ch3m	-35.96
Ch3y	-94.18
Ch5y	-96.86
Ch6m	-56.08
Change	-4.41%
Change From Open	-3.7
Close	1.36
Days Gap	-0.74
Depreciation Amortization	950,000
Dollar Volume	546,548.6
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$-46.7M
EBITDA	$-45.7M
EPS	$-1.61
F Score	0
Fiscal Year End	December
Founded	1,998
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Date	2017-05-10
Last Split Type	Reverse
Last10k Filing Date	2026-03-12
Ma150	2.45
Ma150ch	-46.83%
Ma20	1.56
Ma20ch	-16.45%
Next Earnings Date	2026-05-13
Open	1.35
Optionable	Yes
Position In Range	36.71
Post Close	1.3
Postmarket Change Percent	1.54
Postmarket Price	$1.32
Ppne	20,403,000
Price Date	2026-05-08
Ptbv Ratio	0.92
Relative Volume	0.92x
Tr20y	-96.36%
Tr6m	-56.08%
Us State	Texas
Volume	420,422

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FLNA pay a dividend?

Capital-return profile for this ticker.

Performance

FLNA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FLNA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+28.4%

Float: +93.3% of shares outstanding

Insider ownership

+6.7%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FLNA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

30.2

Neutral momentum band

Price vs 200-day MA

-46.5%

50/200-day relationship not available

Beta (5Y)

-0.76

Less volatile than the market

Sharpe ratio

0.19

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FLNA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current FLNA stock rating?

Filana Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full FLNA analysis?

The full report lives at /stocks/FLNA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for FLNA?

The latest report frames FLNA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the FLNA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.